Global Cardiotoxicity Market Report and Forecast 2024-2032

Cardiotoxicity Market Size

The global cardiotoxicity market is expected to grow at a CAGR of 8.39% during the forecast period of 2024-2032, driven by the growing prevalence of cancer as well as emphasis on its early detection across the globe. 

Cardiotoxicity Market Outlook

• The increasing incidence of cancer is a key cause of cardiotoxicity as it is often associated with a reaction against certain cancer treatments or drugs.

• One of the major market trends is the rising collaborations between pharmaceutical and diagnostic companies.

• North America is expected to lead the market share in the forecast period. This can be attributed to its strong healthcare system and large investments in research.

Cardiotoxicity Market Overview

Cardiotoxicity is a medical phenomenon where the utilization of some chemical agents results in toxic action on cardiac tissue. Cardiotoxicity risk ranges from minimal to severe, depending on the medication used, the dose given, and the period of use. Some of the signs are coughing with or without sputum, dyspnea, chest pain, palpitations, fatigue, and lower extremity edema. In the worst cases, it results in heart failure, as indicated by aspects such as increased weight, breathing problems, and protracted coughing episodes. The diagnosis of this disease begins with a history and physical examination of the patient, followed by an electrocardiogram, echocardiogram, cardiac MRI, blood tests, and even a biopsy, which may occasionally be done.

Cardiotoxicity Market Growth Drivers

Growing Use of Cardiotoxic Drugs to Boost the Market Demand

A rising prevalence of drugs that can harm the heart in cancer treatments is a main force that is propelling the market for cardiotoxicity. Chemotherapeutic agents, targeted therapies, and radiation therapy can cause cardiotoxicity. Moreover, the latest advances in the field of oncology have contributed to the broadened utilization of new chemotherapeutic agents, many of which have cardiotoxicity.

According to the American Cancer Society, the number of new cancer cases in the United States reached 1,958,310, while 609,820 people died from cancer in 2023. This further emphasizes the necessity for heart protection measures, early detection techniques, and all-inclusive management procedures. The growing geriatric population base, which is naturally more susceptible to both cancer as well as other cardiac issues is also boosting the demand for cardiotoxicity monitoring and treatment.

Cardiotoxicity Market Trends

Recent Developments in the Cardiotoxicity Market

The market is witnessing increased research and development initiatives aimed at recognising the main cause of cardiotoxicity. For instance, in April 2024, the scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) reported that anthracyclines, one of the most common chemotherapy treatments, damage patients' hearts. Anthracycline-induced cardiotoxicity affects about one-third of cancer survivors. More than 3 million patients in the European continent are treated with this drug class annually. Around 5% of the patients can get a life-threatening cardiac injury, which may result in chronic heart failure, and disrupt a patient’s quality of life.

Cardiotoxicity Market Segmentation

Market Breakup by Type

• Diagnostic
  • Analyzers and Instruments
  • Reagents and Kits
  • Software and Services 
  • Others

• Treatment
  • Tyrosine Kinase Inhibitors
  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Antibiotics
  • Others

Market Breakup by End User

• Pharmaceutical and Biotechnology Company

• Academic and Research Institutes

• Contact Research Organizations

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Cardiotoxicity Market Share

Market Segmentation by End User Expected to Boost the Market Growth

The market segmentation based on end users, includes pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others. Out of these, pharmaceutical and biotechnology companies are expected to hold a significant market share. It can be attributed to their massive research and development activities, increased investment in advanced technologies, and strong sources for the assessment of cardiac safety.

Cardiotoxicity Market Analysis by Region

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these regions, North America is likely to hold the largest share of the market because of the well-developed infrastructure of the healthcare industry, substantial research expenditure, and a higher incidence of cancer. Europe, with a robust regulatory landscape is expected to hold a notable market share. In the Asia Pacific region, the market potential for Japan and India is on the rise because of the rising healthcare costs, a growing pharmaceutical market, and escalating awareness of the many cardiac health problems.

Leading Players in the Cardiotoxicity Market

The key features of the market report include patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Admescope Ltd

Founded in 2011 and headquartered in Oulu, Finland, this company offers services important and related to the assessment of cardiotoxicity. Their portfolio consists of in vitro assays that include drug metabolism and pharmacokinetics (DMPK), which play an important role in making assessments of the cardiac safety profiles of chemical entities of drugs.

Axol Bioscience Ltd.

Founded in 2013 and headquartered in Cambridge, UK, the company offers commercial products such as cardiotoxicity assay kits that contain reagents and protocols for functional assays as well as toxicity screening in cardiomyocyte models.

Other companies include Evotec BioSystems GmbH, Stemina Biomarker Discovery Inc., Eurofins Panlabs Discovery Services, Molecular Devices LLC., Curia Global Holdings Ltd, Aragen Life Sciences Limited, Anbio Biotechnology Limited, WuXi AppTec Co., Ltd., Creative Bioarray, Emka Technologies Private Limited, Enzo Life Sciences, Inc., Novartis AG, Pfizer & Co., Inc., and Amgen Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been in the report.

Key Highlights of the Report

Key Questions Answered in the Cardiotoxicity Market

• What was the cardiotoxicity market value in 2023?
• What is the cardiotoxicity market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What are the major factors aiding the cardiotoxicity market demand? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• What are the major cardiotoxicity market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the cardiotoxicity market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What is the market segmentation based on type?
• What is the market segmentation based on end user?
• Why do pharmaceutical companies prioritize cardiotoxicity testing?
• How does the regulatory landscape in Europe impact cardiotoxicity testing practices?
• What factors are driving growth in the cardiotoxicity market in the Asia Pacific?